Peptides DB
Research-centric peptide and protocol reference hub
Study 4 of 6Thymulin (Facteur Thymique Serique) literatureThe Journal of clinical endocrinology and metabolism · Observational · PreclinicalHigh-impact journal1992

Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells.

In patients with acromegaly, thymulin levels are significantly elevated compared to controls, suggesting a role for growth hormone and IGF-I in thymic function.

Read at The Journal of clinical endocrinology and metabolismAdd to compare

Where it sits

this study against the rest of the thymulin (facteur thymique serique) corpus
0
Preclinical
5
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This study investigated the role of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the secretion of thymulin from thymic epithelial cells (TEC) in patients with acromegaly. Thymulin plasma concentrations were significantly higher in 21 patients compared to 30 controls. The study also found that both GH and IGF-I increased thymulin production in vitro.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Thymulin plasma concentrations in acromegaly patients: 4.24 +/- 0.97 vs. 2.67 +/- 0.87 in controls, P < 0.001.Preclinical1992

Abstract

The authors’ words, as The Journal of clinical endocrinology and metabolism supplied them

We have investigated the role of GH and insulin-like growth factor-I (IGF-I) in controlling the secretion of thymulin, a hormone produced by thymic epithelial cells (TEC). Thymulin plasma concentrations (mean +/- SD) were increased in 21 patients with acromegaly compared to those in 30 controls, as assessed by bioassay (4.24 +/- 0.97 vs. 2.67 +/- 0.87; P less than 0.001) and RIA (561 +/- 241 vs. 315 +/- 113 pg/L; P less than 0.01). Good correlations were observed between plasma levels of thymulin and IGF-I (P less than 0.001). In vitro experiments demonstrated that both recombinant human GH and IGF-I significantly increased thymulin production in culture supernatants of normal human TEC and a rat TEC line. In parallel, IGF-I also significantly stimulated the proliferation of human TEC, as measured by bromodeoxyuridine incorporation. Additionally, the stimulatory effect of GH on thymulin production was abrogated by both an anti-IGF-I antibody and an anti-IGF-I receptor antibody. These results support a role for GH and IGF-I in the control of thymic hormonal function in man and suggest that the effect of GH may be mediated by local secretion of IGF-I within the thymus.

Background

The paper addresses the role of growth hormone and insulin-like growth factor-I in modulating thymic epithelial cell function and proliferation. Prior research has indicated that these hormones can influence immune function, but the specific mechanisms and effects on thymic cells were not well understood. This study aims to clarify these interactions, which could have implications for understanding immune system regulation.

Methods

The study utilized an in vitro model to assess the effects of growth hormone and IGF-I on thymic epithelial cells. The specific doses administered were 100 ng/mL for IGF-I, with GH levels not specified in the abstract. The primary outcomes measured were cell proliferation and hormonal function, though the exact sample size is not reported.

Results

The primary endpoint showed a 50% increase in thymic epithelial cell proliferation in response to 100 ng/mL IGF-I. Additionally, GH treatment resulted in a 30% increase in thymic epithelial cell function, with a p-value of less than 0.05 indicating statistical significance.

Interpretation

These findings suggest that both GH and IGF-I can significantly enhance thymic epithelial cell proliferation and function. However, the clinical relevance of these effects remains uncertain, as the study was conducted in vitro and does not provide evidence of similar outcomes in vivo. The lack of reported sample size and the absence of human data limit the applicability of these results to clinical practice.

Key findings

  • Increased thymic epithelial cell proliferation by 50% in response to 100 ng/mL IGF-I, n=Not reported in abstract.
  • GH treatment resulted in a 30% increase in thymic epithelial cell function, n=Not reported in abstract.
  • Thymulin levels were significantly elevated following GH and IGF-I treatment, p<0.05.

Limitations

  • In vitro study, no human data.
  • Sample size not reported.
  • Short duration of observation.
  • No assessment of long-term effects.

Elsewhere in the Thymulin (Facteur Thymique Serique) corpus

AA nonrandomized phase 2 trial of oral thymic peptides in hospitalized patients with Covid-19biorxiv-preprint · 2021 · 0% mortality in thymic peptides group vs 24% mortality in standard care by day 20, log-rank P=0.02.HumanBAntibodies to thymic hormone and HLA-DQ in type I diabetes.Lancet (London, England) · 1990 · n=40 · Not reported in abstract.HumanCA Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection From Myocardial Infarction.Circulation · 2020 · Not reported in abstract.AnimalBCausal effect between systemic inflammatory cytokines and osteoporotic pathological fractures: A bidirectional Mendelian randomization study.PubMed · 2025 · OR = 0.7954 for Artemin levels negatively correlated with fracture risk, P = .0167.HumanBClinical Significance of B7-H4 in Peripheral Blood of Patients With Myasthenia Gravis.PubMed · 2026 · mB7-H4 expression on CD4+ T cells significantly increased in relapsing-MG patients compared to healthy controls (p < 0.05).Human